Retatrutide, a innovative dual-acting glucose-responsive incretin agent, represents a significant advance in peptide medicines for the management of type 2 diabetic conditions and, increasingly, obesity. Unlike Selank many existing medicinal interventions, retatrutide integrates the actions of a GLP-1 receptor stimulant and a GIP receptor agonist,